Permanent Dual-chamber cardiac pacing has been proposed as treatment of advanced cardiac failure due to ischaemic or primary dilated, hypokinetic cardiomyopathies, since 1986. After encouraging initial results in 1990, the most recent studies have reported less convincing results, justifying the need for prospective, randomised studies. The physiopathological mechanisms underlying the haemodynamic improvement remain unknown.